Disproportionality Analysis of the Five Most Widespread Neurological Effects of COVID-19 Vaccines from 2021 to 2023: Insights from EudraVigilance
<b>Background/Objectives:</b> Post-market surveillance of COVID-19 vaccines is vital. This study analyzed EudraVigilance data (Jan 2021–Dec 2023) to detect potential safety signals linking COVID-19 vaccines and specific neurological adverse events (aseptic meningitis, Guillain–Barré synd...
Saved in:
| Main Authors: | Arturo Gómez López de las Huertas, Stefan Stewart, Mikel Urroz Elizalde, Javier Guijarro-Eguinoa, Enrique Seco-Meseguer, Elena Diago-Sempere, María Jiménez González, Antonio J. Carcas-Sansuan, Alberto M. Borobia Pérez, Elena Ramírez |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/5/636 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploring the Cardiovascular Safety Profile of Ibuprofen: Insights from EudraVigilance Database
by: Cristina Anamaria Buciuman, et al.
Published: (2025-07-01) -
Safety profile of tirzepatide: A real-world pharmacovigilance analysis of EudraVigilance database
by: Atul Khurana, et al.
Published: (2024-11-01) -
Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance
by: Ioana Rada Popa Ilie, et al.
Published: (2024-12-01) -
Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance
by: Desirèe Speranza, et al.
Published: (2025-04-01) -
Comparative Pharmacovigilance Analysis of Approved and Repurposed Antivirals for COVID-19: Insights from EudraVigilance Data
by: Paul Andrei Negru, et al.
Published: (2025-06-01)